Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 33 citing articles:

Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
Alise Carlson, Moein Amin, Jeffrey A. Cohen
Drugs (2024) Vol. 84, Iss. 3, pp. 285-304
Open Access | Times Cited: 15
The relative risk of infection in people with multiple sclerosis using disease-modifying treatment: a systematic review of observational studies
Melissa Wing Yee Leung, E.M.W. van de Garde, Bernard M.J. Uitdehaag, et al.
Neurological Sciences (2025)
Open Access
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab
René Carvajal, Ana Zabalza, Pere Carbonell‐Mirabent, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e246345-e246345
Open Access | Times Cited: 4
Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study
Suvi Virtanen, Fredrik Piehl, Thomas Frisell
Journal of Neurology Neurosurgery & Psychiatry (2024) Vol. 95, Iss. 12, pp. 1150-1157
Open Access | Times Cited: 4
Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis
Yihan Hu, Thomas Frisell, Peter Alping, et al.
Annals of Neurology (2024) Vol. 96, Iss. 4, pp. 694-703
Open Access | Times Cited: 3
Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups
Lamiae Grimaldi‐Bensouda, Caroline Papeix, Yann Hamon, et al.
JAMA Neurology (2023) Vol. 80, Iss. 10, pp. 1098-1098
Open Access | Times Cited: 7
A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients
René Carvajal, Carmen Tur, Xavier Martínez‐Gómez, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 14, pp. 1841-1848
Open Access | Times Cited: 7
De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis
Robert Gross, John R. Corboy
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 9, pp. 341-353
Closed Access | Times Cited: 2
Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies
Susana Sainz de la Maza, Paulette Esperanza Walo-Delgado, Mario Rodríguez-Domínguez, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 786-786
Open Access | Times Cited: 6
Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs
Berenice Silva, Edgar Carnero Contentti, Jéfferson Becker, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 77, pp. 104840-104840
Closed Access | Times Cited: 6
Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
Lina Jeantin, Basma Abdi, Cathia Soulié, et al.
Journal of Neurology Neurosurgery & Psychiatry (2023) Vol. 95, Iss. 1, pp. 19-28
Closed Access | Times Cited: 4
Infektionen und Multiple Sklerose
Felicita Heidler, Tobias Bopp, Matthias Schwab, et al.
Fortschritte der Neurologie · Psychiatrie (2024)
Closed Access | Times Cited: 1
Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry
Nadine Bast, Karen Dost-Kovalsky, Sabrina Haben, et al.
The Lancet Regional Health - Europe (2024) Vol. 48, pp. 101137-101137
Closed Access | Times Cited: 1
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab
Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 72, pp. 104616-104616
Open Access | Times Cited: 4
Three to four mRNA COVID‐19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization
Céline Louapre, Lisa Belin, Stéphane Marot, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 9, pp. 2781-2792
Open Access | Times Cited: 3
Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis
Fan Ning, Xiang-qi Cao, Qingqing Wang, et al.
Heliyon (2023) Vol. 10, Iss. 1, pp. e23944-e23944
Open Access | Times Cited: 3
Vaccine hesitancy in people with multiple sclerosis
Jeannette Lechner‐Scott, Joshua S. Davis, Christopher H. Hawkes, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 65, pp. 104102-104102
Open Access | Times Cited: 5
Vaccine response in people with multiple sclerosis treated with fumarates
Matthew Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2023) Vol. 9, Iss. 3
Open Access | Times Cited: 2
Rethinking vaccination in multiple sclerosis: The way forward
Saúl Reyes, Susana Otero‐Romero
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 11-12, pp. 1351-1352
Open Access | Times Cited: 2
Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study
Jonas Graf, Huah Shin Ng, Feng Zhu, et al.
The Lancet Regional Health - Americas (2024) Vol. 29, pp. 100667-100667
Open Access
Comorbilidades en la esclerosis múltiple y su influencia en la elección del tratamiento
Andrés Barboza, Vladimiro Sinay, Ricardo Alonso, et al.
Revista de Neurología (2024) Vol. 78, Iss. 06, pp. 157-157
Open Access
Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders
Mohammad Yazdan Panah, Saeed Vaheb, Yousef Mokary, et al.
Vaccine (2024) Vol. 42, Iss. 23, pp. 126061-126061
Closed Access
The Characterization of the Th1/Th2 Ratio in Multiple Sclerosis Patients and its Response to a Dietary Supplement Regimen
John E. Lewis, H. Reginald McDaniel, Judi M. Woolger, et al.
Journal of Dietary Supplements (2024) Vol. 21, Iss. 6, pp. 771-790
Closed Access
The Impact of Disease-Modifying Therapies of Multiple Sclerosis on the Effectiveness of the BBIBP-CorV COVID-19 Vaccine
Mehran Ghaffari, Nahid Beladi Moghadam, Sepideh Paybast, et al.
Archives of Clinical Infectious Diseases (2024) Vol. 19, Iss. 6
Open Access
Antibiotic Utilization Among People With Multiple Sclerosis in the Netherlands, 2018–2020
Melissa Wing Yee Leung, Marloes T. Bazelier, Bernard M.J. Uitdehaag, et al.
Pharmacoepidemiology and Drug Safety (2024) Vol. 33, Iss. 12
Open Access
Page 1 - Next Page

Scroll to top